3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Doseology Sciences does not have enough data to calculate 3-Year ROIIC %.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Doseology Sciences 3-Year ROIIC % Related Terms
Doseology Sciences 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Doseology Sciences's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DOSEF vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Doseology Sciences's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Doseology Sciences 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Doseology Sciences's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Doseology Sciences's 3-Year ROIIC % falls into.
Doseology Sciences's 3-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -0.345 (Jun. 2025) - -1.419 (Jun. 2022) )
/
( 0 (Jun. 2025) - 1.46 (Jun. 2022) )
=
1.074
/
=
N/A%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Doseology Sciences (DOSEF) has a 3-Year ROIIC % of 0.00 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Doseology Sciences and its competitors. Over the past decade, Doseology Sciences' 3-Year ROIIC % has ranged from 63.39 to 63.39. According to the industry distribution chart, Doseology Sciences ranks #999999 out of 1318 companies in the Biotechnology industry.
Is Doseology Sciences' 3-Year ROIIC % too high?
Doseology Sciences' current 3-Year ROIIC % is 0.00. Over the past 10 years, this metric has ranged from a low of 63.39 to a high of 63.39. Based on the distribution chart, Doseology Sciences ranks #999999 out of 1318 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Doseology Sciences has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Doseology Sciences' 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Doseology Sciences ranks #999999 out of 1318 companies for 3-Year ROIIC %. This places Doseology Sciences in the lower half of its industry. Historically, Doseology Sciences' own 3-Year ROIIC % has ranged from 63.39 to 63.39 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Doseology Sciences and its competitors. Doseology Sciences's current 3-Year ROIIC % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Doseology Sciences stock overvalued right now?
Based on GuruFocus' analysis, Doseology Sciences (DOSEF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.29, compared to a current price of $0.11 — trading 61.3% below its estimated fair value. The current 3-Year ROIIC % is 0.00. Doseology Sciences' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Doseology Sciences (DOSEF), the current 3-Year ROIIC % is 0.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Doseology Sciences (DOSEF) Overvalued in 2026?
Based on GuruFocus' analysis, Doseology Sciences stock appears to be undervalued.
The current stock price of $0.11 is trading 61.3% below its estimated GF Value™ of $0.29.
GuruFocus considers Doseology Sciences to be Possible Value Trap.
Key valuation signals for DOSEF:
3-Year ROIIC %: 0.00
GF Value™: $0.29 vs. price of $0.11 (61.3% below fair value)
No single metric tells the full story. See the DOSEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Doseology Sciences Inc is a diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on the psychedelic and non-psychedelic compounds, also sale of its branded functional mushroom products. It offers cutting-edge therapeutic products and services, with the focus of making a meaningful impact on the mental health pandemic and improving overall health. Geographically earns it revenue from Canada.
31GF Score
Get the complete analysis for DOSEF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DOSEF has been successfully added to your 
